| Title : [New drugs\; exenatide and sitagliptin] - van Bronswijk_2008_Ned.Tijdschr.Geneeskd_152_876 |
| Author(s) : van Bronswijk H , Dubois EA , Pijl H , Cohen AF |
| Ref : Ned Tijdschr Geneeskd , 152 :876 , 2008 |
|
Abstract :
Incretin hormones, secreted upon food intake, play an important role in the regulation of blood glucose levels. In type 2 diabetes mellitus, the incretin response is decreased. Substitution of incretin is a novel pharmacological target which restores postprandial glucose homeostasis. Exenatide is a mimetic of the incretin glucagon-like peptide-I (GLP-I). Sitagliptin is an inhibitor of the enzyme dipeptidyl peptidase 4 (DPP-4), which breaks down GLP-I. Both drugs increase the GLP-I concentration, thereby improving insulin secretion from pancreatic p cells, restoring glycaemic control, preventing beta cell destruction, delaying gastric emptying, and reducing food intake. |
| PubMedSearch : van Bronswijk_2008_Ned.Tijdschr.Geneeskd_152_876 |
| PubMedID: 18512528 |
| Inhibitor | Sitagliptin |
van Bronswijk H, Dubois EA, Pijl H, Cohen AF (2008)
[New drugs\; exenatide and sitagliptin]
Ned Tijdschr Geneeskd
152 :876
van Bronswijk H, Dubois EA, Pijl H, Cohen AF (2008)
Ned Tijdschr Geneeskd
152 :876